Contact Us
Please complete the form, and a representative of Intelligent Bio Solutions will contact you shortly to assist with your enquiry.
Our Locations
New York
Intelligent Bio Solutions Inc.
Floor 5, 135 W 41st St,
New York, NY 10036,
United States
+1 646 790 5756
Office Hours
9am – 5pm Monday to Friday
Sydney
Intelligent Bio Solutions Inc.
Level 1, Suite 5,
28-40 Lord Street,
Botany, NSW, 2019
Australia
Office Hours
9am – 5pm Monday to Friday
Cambridge
14-17 Evolution Business Park,
Milton Road, Impington,
Cambridge, CB24 9NG,
United Kingdom
info@intelligentfingerprinting.com
+44 (0)1223 941941
Office Hours
9am – 5pm Monday to Friday
Media Contact
For media enquiries, please contact marketing@ibs.inc.
Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
Find more information at investors.ibs.inc.
Connect With Us
Latest News

Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
NEW YORK, November 10, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2026. “Fiscal first quarter revenue was the highest quarterly revenue in our Company’s…

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
NEW YORK, September 09, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “System”)…

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
NEW YORK, September 01, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the results of its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System (the “System”) to detect the opiate codeine. Conducted across three independent U.S….